Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Recreational drugs: a new health hazard for patients with concomitant chronic liver diseases.

Tarantino G, Citro V, Finelli C.

J Gastrointestin Liver Dis. 2014 Mar;23(1):79-84. Review.

2.

Interaction of non-alcoholic fatty liver disease with other liver diseases.

Clouston AD, Powell EE.

Best Pract Res Clin Gastroenterol. 2002 Oct;16(5):767-81. Review.

PMID:
12406444
3.

Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake.

Mundt B, Wirth T, Zender L, Waltemathe M, Trautwein C, Manns MP, Kühnel F, Kubicka S.

Gut. 2005 Nov;54(11):1590-6.

4.

Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey.

Tokushige K, Hashimoto E, Horie Y, Taniai M, Higuchi S.

J Gastroenterol. 2011 Oct;46(10):1230-7. doi: 10.1007/s00535-011-0431-9. Epub 2011 Jul 13.

PMID:
21748549
5.

[Comorbidity and hepatotoxicity of tobacco and recreational substances].

Hezode C, Mallat A.

Gastroenterol Clin Biol. 2009 Dec;33(12):1131-5. doi: 10.1016/j.gcb.2009.10.008. Epub . French. No abstract available.

6.

Predictive factors for the severity of liver fibrosis in patients with chronic hepatitis C and moderate alcohol consumption.

Vădan R, Gheorghe L, Becheanu G, Iacob R, Iacob S, Gheorghe C.

Rom J Gastroenterol. 2003 Sep;12(3):183-7.

PMID:
14502317
7.

Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.

Miquilena-Colina ME, Lima-Cabello E, Sánchez-Campos S, García-Mediavilla MV, Fernández-Bermejo M, Lozano-Rodríguez T, Vargas-Castrillón J, Buqué X, Ochoa B, Aspichueta P, González-Gallego J, García-Monzón C.

Gut. 2011 Oct;60(10):1394-402. doi: 10.1136/gut.2010.222844. Epub 2011 Jan 26.

PMID:
21270117
9.

Obesity and non-alcoholic fatty liver disease in chronic hepatitis C.

Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A, Bringman D, Martin LM, Assmann J, Gramlich T, Mullen KD, O'Shea R, Carey WD, Ferguson R.

J Clin Gastroenterol. 2004 Sep;38(8):705-9.

PMID:
15319656
10.

Alcohol's effect on other chronic liver diseases.

Lee M, Kowdley KV.

Clin Liver Dis. 2012 Nov;16(4):827-37. doi: 10.1016/j.cld.2012.08.010. Review.

PMID:
23101984
11.

Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications.

Tsochatzis EA, Manolakopoulos S, Papatheodoridis GV, Archimandritis AJ.

Scand J Gastroenterol. 2009;44(1):6-14. doi: 10.1080/00365520802273058. Review.

PMID:
18661429
12.

Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis.

Gaia S, Carenzi S, Barilli AL, Bugianesi E, Smedile A, Brunello F, Marzano A, Rizzetto M.

J Hepatol. 2011 Jan;54(1):64-71. doi: 10.1016/j.jhep.2010.06.022. Epub 2010 Aug 21.

PMID:
20932598
13.

The impact of diet on liver fibrosis and on response to interferon therapy in patients with HCV-related chronic hepatitis.

Loguercio C, Federico A, Masarone M, Torella R, Blanco Cdel V, Persico M.

Am J Gastroenterol. 2008 Dec;103(12):3159-66. doi: 10.1111/j.1572-0241.2008.02159.x. Epub 2008 Sep 11.

PMID:
18786125
14.

Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C.

Vidali M, Occhino G, Ivaldi A, Rigamonti C, Sartori M, Albano E.

Am J Gastroenterol. 2008 Jan;103(1):147-53. doi: 10.1111/j.1572-0241.2007.01596.x.

PMID:
18184121
15.

[Acting out and psychoactive substances: alcohol, drugs, illicit substances].

Gillet C, Polard E, Mauduit N, Allain H.

Encephale. 2001 Jul-Aug;27(4):351-9. Review. French.

PMID:
11686057
16.

HAART and the liver: friend or foe?

Pineda JA, Macías J, Mira JA, Merchante N, del Valle J, Neukam KI.

Eur J Med Res. 2010 Mar 30;15(3):93-6.

17.

Non-alcoholic fatty liver disease and hepatitis C infection.

Bondini S, Younossi ZM.

Minerva Gastroenterol Dietol. 2006 Jun;52(2):135-43. Review.

PMID:
16557185
18.
19.

Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C.

Hézode C, Zafrani ES, Roudot-Thoraval F, Costentin C, Hessami A, Bouvier-Alias M, Medkour F, Pawlostky JM, Lotersztajn S, Mallat A.

Gastroenterology. 2008 Feb;134(2):432-9. doi: 10.1053/j.gastro.2007.11.039. Epub 2007 Nov 28.

PMID:
18242211
20.

A comparison of fibrosis progression in chronic liver diseases.

Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P; PANFIBROSIS Group.

J Hepatol. 2003 Mar;38(3):257-65.

PMID:
12586290
Items per page

Supplemental Content

Write to the Help Desk